source
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.BioPharma Dive · 2mo ago↗ source
- Full-Life Technologies raises $150M; Quince's reboot with pulmonary drugPlus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised $110 million in a Series D round an…Endpoints · 2mo ago↗ source
- Relay drug shows early promise against rare blood vessel diseasesWhile early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.